Study of phospho-β-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome

Modern Pathology

Volumn 19, Issue 4, 2006, Pages 556-563

  Nakopoulou, Lydia ^a,b   Mylona, Eleni ^b   Papadaki, Ioanna ^b   Kavantzas, N ^b   Giannopoulou, I ^b   Markaki, S ^c   Keramopoulos, A ^c  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ALEXANDRA HOSPITAL   (Greece)

Author keywords

Breast cancer; Immunohistochemistry; Phospho catenin

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; PROTEINASE ACTIVATED RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER STAGING; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; NUCLEAR LOCALIZATION SIGNAL; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; BREAST NEOPLASMS; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM INVASIVENESS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS;

EID: 33645313198     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800562     Document Type: Article

References (34)

1. Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 1989;8:1711-1717.
2. Morin PJ. B-catenin signaling and cancer. Bioessays 1999;21:1021-1030.
3. Kikuchi A. Regulation of β-catenin signaling in the Wnt pathway. Biochem Biophys Res Commun 2000;268:243-248.
4. Nelson WJ, Nusse R. Convergence of Wnt, β-catenin and cadherin pathways. Science 2004;303:1483-1487.
5. Bienz M. TCF: Transcriptional activator or repressor? Curr Opin Cell Biol 1998;10:366-372.
6. He TC, Sparks AB, Rago C, et al. Identification of C-MYC as a target of the APC pathway. Science 1998;281:1509-1512.
7. Tetsu O, McCormick F. Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (London) 1999;398:422-426.
8. Crawford HC, Fingleton BM, Rudolph-Owen LA, et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999;18:2883-2891.
9. Mann B, Gelos M, Siedow A, et al. Target genes of β-catenin-T cell factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999;96:1603-1608.
10. Abraham SC, Nobukawa B, Giardiello FM, et al. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol 2001;158:1005-1010.
11. Garcia-Rostan G, Tallini G, Herrero A, et al. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 1999;59:1811-1815.
12. Moreno-Bueno G, Gamallo C, Perez-Gallego L, et al. Beta-catenin expression pattern, beta-catenin gene mutations and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Molec Pathol 2001;10:116-122.
13. Rimm DL, Caca K, Hu G, et al. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 in malignant melanoma. Am J Pathol 1999;154:325-329.
14. Lin SY, Xia W, Wang JC, et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 2000;97:4262-4266.
15. Kielhorn E, Provost E, Olsen D, et al. Tissue microarray-based analysis shows phospho-β-catenin expression in malignant melanoma is associated with poor outcome. Int J Cancer 2003;103:652-656.
16. Chung GG, Provost E, Kielhorn EP, et al. Tissue microarray analysis of β-catenin in colorectal cancer shows nuclear phospho-β-catenin is associated with a better prognosis. Clin Cancer Res 2001;7:4013-4020.
17. Tavassoeli FA, Devilee P. Pathology and genetics - tumours of the breast and female genital organs. IARC WHO Classification of Tumours, No. 4, 2003, pp. 10-111.
18. Elston CWL. Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ (eds). Diagnostic Histopathology of the Breast. Churchill Livingstone: Edinburgh, 1987, pp. 300-311.
19. Union International Contre Cancer. TNM classification of International Union against Cancer. In: Hermanek, Sabin LH (eds). TNM Atlas, 4th edn, 3rd revision. Springer-Verlag: Berlin, 1992.
20. Karayiannakis AJ, Nakopoulou L, Gakiopoulou H, et al. Expression patterns of β-catenin in in situ and invasive breast cancer. EJSO 2001;27:31-36.
21. McClelland RA, Wilson D, Leake R, et al. A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. Eur J Cancer 1991;27:711-715.
22. Pavlopoulos PM, Davaris P. Software development for the evaluation of histochemical and immunohistochemical color images Presented at the 24th Annual Panhellenic. Medical Congress, Athens, Greece, May 5-9, 1998.
23. Pavlopoulos PM, Konstantinidou A, Agapitos E, et al. A morphometric study of neovascularization in colorectal carcinoma. Cancer 1998;83:2067-2075.
24. Cardona-Gomez P, Perez M, Avila J, et al. Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3 and β-catenin in the hippocampus. Mol Cell Neurosci 2004;25:363-373.
25. Gunin AG, Emelianov VU, Mironkin IU, et al. Lithium treatment enhances estradiol-induced proliferation and hyperplasia in the uterus of mice. Eur J Obstet Gynecol Reprod Biol 2004;114:83-91.
26. Kouzmenko AP, Takeyama K, Ito S, et al. Wnt/β-catenin and estrogen signaling converge in vivo. J Biol Chem 2004;279:40255-40258.
27. Kirkin Y, Joos S, Zörnig M. The role of bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004;1644:229-249.
28. Wong N-A, Pignatelli M. B-catenin-a linchpin in colorectal carcinogenesis? Am J Pathol 2002;160:389-401.
29. Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000;24:245-250.
30. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-283.
31. Bertaux B, Hornebeck W, Eisen AZ, et al. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 1991;97:679-685.
32. Hayakawa T, Yamashita K, Tanzawa K, et al. Growth-promoting activity ot tissue inhibitor of metalloproteinases-1 (TMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992;298:29-32.
33. Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999;59:6267-6275.
34. Jensen EV, Chen G, Palmieri C, et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 2001;98:15197-15202.